Corbus Pharmaceuticals Holdings, Inc. Stock
Equities
CRBP
US21833P3010
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.77 USD | +1.49% | +13.20% | +541.89% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 407M |
---|---|---|---|---|---|
Net income 2024 * | -53M | Net income 2025 * | -65M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.45
x | P/E ratio 2025 * |
-7.57
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.31% |
Latest transcript on Corbus Pharmaceuticals Holdings, Inc.
1 day | +1.49% | ||
1 week | +13.20% | ||
Current month | +4.67% | ||
1 month | -3.00% | ||
3 months | +48.20% | ||
6 months | +641.30% | ||
Current year | +541.89% |
Managers | Title | Age | Since |
---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Sean Moran
DFI | Director of Finance/CFO | 66 | 14-04-10 |
Chief Tech/Sci/R&D Officer | 50 | Feb. 27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Holmer
CHM | Chairman | 74 | 13-12-31 |
Avery Catlin
BRD | Director/Board Member | 75 | 14-07-31 |
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 38.77 | +1.49% | 134,688 |
24-05-02 | 38.2 | +2.55% | 180,369 |
24-05-01 | 37.25 | +0.57% | 133,291 |
24-04-30 | 37.04 | +3.93% | 197,603 |
24-04-29 | 35.64 | +4.06% | 92,849 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+541.89% | 407M | |
+8.96% | 105B | |
-1.43% | 104B | |
+5.30% | 22.94B | |
-12.15% | 22.34B | |
-6.45% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- CRBP Stock